Search

Your search keyword '"Holly Delgado"' showing total 2 results
Start Over Author "Holly Delgado" Journal neurology
2 results on '"Holly Delgado"'

1. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

Author

Margaret Marie Cox, Stephanie Sendek, Margaret F. Turk, Julie H. Carter, Susan C. Fagan, Lorelei Derwent, Oksana Suchowersky, Jay S. Schneider, Linda Paul, Gwyn Vernon, Stephen Gollomp, Karl Kieburtz, Debbie Baker, I. Van Bodis-Wollner, Germaine McInnes, Marian A. Perez, G. Webster Ross, Katharine Pabst, Jorge L. Juncos, Chad W. Christine, Jessie Roth, Joseph M. Savitt, Peter A LeWitt, Hubert H. Fernandez, Matthew Brodsky, Mark F. Lew, Jay M. Gorell, Natividad R. Stover, Paulo Guimaraes, Andrew Feigin, Anita Blenke, Martha Nance, Elizabeth Hayes, Andrew Siderowf, W.R. Wayne Martin, Tammie Kelsey, Susan Bennett, Sharon McCarthy, Charles H. Adler, Beverly Olsen, Pauline LeBlanc, Richard B. Dewey, Rodger J. Elble, Richard S. Burns, Carlos Singer, Amy Parsons, John W. Taylor, Tracy Stewart, Maryan DeAngelis, Barbara C. Tilley, William J. Weiner, Brad A. Racette, Wendy R. Galpern, Michael J. Aminoff, Kapil D. Sethi, Jayaraman Rao, Robert A. Hauser, Debbie Fraser, Connie Kawai, David Coffey, Kelly E. Lyons, Kristine Wernette, Becky Dunlop, Holly Delgado, Marlene Lind, Rajesh Pahwa, Chris Weaver, Ray L. Watts, Patricia Deppen, Ryan J. Uitti, Marwan N. Sabbagh, Lynn Marlor, Joann Belden, Burton L. Scott, Theresa McClain, Roger L. Albin, John Y. Fang, Zoran Obradov, Yuko Y. Palesch, Maureen Cook, Pamela Andrews, Jeana Jaglin, Joanne Wojcieszek, Mary Louise Musante Weeks, Susan Peterson, James H. Bower, Maureen A. Leehey, Joanne Field, Lisa M. Shulman, Caroline M. Tanner, Jacob I. Sage, Jordan J. Elm, Joseph Jankovic, Patrick D. Mauldin, Aileen Shinaman, Peng Huang, G. Frederick Wooten, Alicia Brocht, Gordon H. Brown, Peggy Roberge, Dorothy Shearon, Buff Dill, Margaret F. Keller, Charlene Young, Christine Hunter, Janis M. Miyasaki, Susan Torgrimson, Cornelia Kamp, Brigid Hayward, Christopher G. Goetz, Emily Kosa, Marilyn Flewellen, David Simon, Rebecca McMurray, Sue Reichwein, Jacci Bainbridge, Robert W. Hamill, Stephanie Terashita, Kathleen M. Shannon, Frederick Wooten, Danna Jennings, Shana Krstevska, and Bernard Ravina

Subjects
Male, medicine.medical_specialty, Future studies, Neurology, Ubiquinone, Coenzymes, Disease, Placebo, Tacrolimus, law.invention, chemistry.chemical_compound, Double-Blind Method, Randomized controlled trial, law, Rating scale, Internal medicine, Humans, Medicine, Aged, Coenzyme Q10, business.industry, Headache, Nausea, Parkinson Disease, Middle Aged, Clinical trial, chemistry, Physical therapy, Female, Neurology (clinical), business
Abstract

Objective: To determine if future studies of coenzyme Q10 and GPI-1485 in Parkinson disease (PD) may be warranted. Methods: We conducted a randomized, double-blind, calibrated futility clinical trial of coenzyme Q10 and GPI-1485 in early untreated PD using placebo data from the DATATOP study to establish the futility threshold. Results: The primary outcome measure (change in total Unified Parkinson's Disease Rating Scale scores over 1 year) did not meet the prespecified criteria for futility for either agent. Secondary analyses using calibration controls and other more recent placebo data question the appropriateness of the predetermined definition of futility, and suggest that a more restrictive threshold may be needed. Conclusions: Coenzyme Q10 and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent. Additional factors (cost, availability of other agents, more recent data on placebo outcomes, other ongoing trials) should also be considered in the selection of agents for Phase III studies. NEUROLOGY 2007;68:20-28

Published
2007

2. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

Author

Carolyn Peterson, Peggy Gray, Anette Nieves, Julie H. Carter, Lauren Seeberger, William C. Nichols, John M. Bertoni, Anja Rudolph, Francis O. Walker, Juliette Harris, L. Liu, Un Jung Kang, P. M. Conneally, Kenneth Marek, Alex Rajput, Shirley Uy, Michael Panisset, Becky Dunlop, Margaret C. Lannon, Stephen G. Reich, Frederick J. Marshall, Kelly E. Lyons, Stephanie Thomas, Karen Bindauer, Ronald F. Pfeiffer, Maryan DeAngelis, David Oakes, William J. Weiner, Jean P. Hubble, Joseph H. Friedman, Deborah Fontaine, Victoria Hunt, Karyn Boyer, Richard Camicioli, Julie So, Theresa Shirley, Christopher F. O'Brien, Carmen Serrano Ramos, Sean K. Uniacke, Lawrence I. Golbe, Eric Siemers, Roger Kurlan, Kelli Williamson, Cheryl Halter, Brenda Pfeiffer, Karen Marder, Jean Hall, Clifford W. Shults, Peter A. LeWitt, Lisa Scollins, Judith Dobson, Robert L. Rodnitzky, Lawrence Elmer, Hubert H. Fernandez, Jeannine Petit, Tatiana Foroud, Susan Mendick, Deborah Judd, Joseph Jankovic, Paul Gordon, Anhoa Tran, Rajesh Pahwa, Aileen Shinaman, Sandra Roque, Paul J. Tuite, David Simon, Joanna Hamann, Danna Jennings, Christine Hunter, Daniel D. Truong, Holly Delgado, Theresa A. Zesiewicz, Pamela Andrews, Michael J. Aminoff, Mark Stacy, Debra Berry, Sharon Evans, W.R. Wayne Martin, Robert A. Hauser, Nathan Pankratz, Mariann DiMinno, William C. Koller, Bala V. Manyam, Marguerite Wieler, Carson Reider, Kathy Davis, Mayank Pathak, Patricia Simpson, Mark Forrest Gordon, David Grimes, Magali Fernandez, Joann Belden, Joanne Wojcieszek, Robyn Schacherer, Tilak Mendis, Rachel Saunders Pullman, Ali H. Rajput, Juan Sanchez-Ramos, and Stewart A. Factor

Subjects
Genetics, Mutation, Heterozygote, Ubiquitin-Protein Ligases, Parkinson Disease, Biology, Middle Aged, medicine.disease_cause, Genetic determinism, Parkin, nervous system diseases, Loss of heterozygosity, Genotype, North America, medicine, Humans, Neurology (clinical), Genetic Testing, Allele, Age of onset, Age of Onset, Exome sequencing, Aged
Abstract

Background: The vast majority of the parkin mutations previously identified have been found in individuals with juvenile or early onset PD. Previous screening of later onset PD cohorts has not identified substantial numbers of parkin mutations. Methods: Families with at least two siblings with PD were ascertained to identify genes contributing to PD susceptibility. Screening of the parkin gene, by both quantitative PCR and exon sequencing, was performed in those families with either early onset PD (age onset ≤50 years) or positive lod score with a marker in intron 7 of the parkin gene. Results: A total of 25 different mutations in the parkin gene were identified in 103 individuals from 47 families. Mutations were found in both parkin alleles in 41 of the individuals, whereas a single mutation in only one of the two parkin alleles was observed in 62 individuals. Thirty-five of the subjects (34%) with a parkin mutation had an age at onset of 60 years or above with 30 of these 35 (86%) having a detectable mutation on only one parkin allele. Few significant clinical differences were observed among the individuals with two, one, or no mutated copies of the parkin gene. Conclusion: Mutations in the parkin gene occur among individuals with PD with an older age at onset (≥60 years) who have a positive family history of the disease. In addition, the clinical findings of parkin -positive individuals are remarkably similar to those without mutations.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results